New Zealand govt “tinkers around R&D tax deductibility,” says Labour

9 November 2013

New Zealand’s National Party Government’s call for feedback to resolve problems around the tax deductibility of R&D expenditure for businesses is more tinkering and shows a government out of touch with the needs of business, says the Labour Party’s Innovation, Research & Development spokesperson Megan Woods and Revenue spokesperson David Clark.

"We don’t need small scale thinking, we need a big bold initiative that will allow businesses to do what they do best: innovate," says Megan Woods, in a report posted on trade group NZBIO’s web site.

"Steven Joyce [Economic Development Minister] and Todd McClay [Associate Minister of Health] have admitted that our tax system is getting in the way of New Zealand businesses’ ability to innovate and reach their potential. They know there is a link between our tax system and innovation. This latest announcement is nothing more than further tinkering around the edges," says Mr Clark.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical